{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:33:23Z","timestamp":1785306803993,"version":"3.55.0"},"reference-count":66,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Histologic transformation from adenocarcinoma to squamous cell carcinoma in lung cancer has not been reported as a mechanism of resistance to ALK inhibition. This report describes the clinical course of a female former light smoker with metastatic lung adenocarcinoma whose tumor underwent histologic transformation from a well-differentiated lung adenocarcinoma to a well-differentiated lung squamous cell carcinoma in the same location at the left mainstem bronchus while maintaining the<jats:italic>ALK<\/jats:italic>fusion oncogene without any resistance mutations. After experiencing disease progression while on crizotinib, the patient participated in clinical trials that provided early access to the novel ALK inhibitors ceritinib and alectinib before they were commercially available. Tumor recurrence occurred at the primary and metastatic central nervous system sites (ie, brain and spine). At tumor progression, liquid biopsy and tumor genomic profiling of plasma cell-free DNA next-generation sequencing (NGS) provided an accurate diagnosis with a short turnaround time compared with the tissue-based targeted capture NGS. The patient received several courses of radiation primarily to the brain and spine during her disease course. Her disease did not respond to the immune checkpoint inhibitor nivolumab, and she died on home hospice approximately 4 years after diagnosis. This case supports the importance of both histopathologic assessment and comprehensive genomic profiling in selecting appropriate treatment for patients with refractory, metastatic,<jats:italic>ALK<\/jats:italic>oncogene\u2013driven non\u2013small cell lung cancer. Use of symptom-directed radiation in tandem with ALK inhibitors contributed to the disease and symptomatic control and prolonged survival in this patient.<\/jats:p>","DOI":"10.6004\/jnccn.2019.7291","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T18:33:40Z","timestamp":1554748420000},"page":"297-301","source":"Crossref","is-referenced-by-count":24,"title":["Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors"],"prefix":"10.6004","volume":"17","author":[{"given":"Jay","family":"Gong","sequence":"first","affiliation":[{"name":"aDivision of Hematology\/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento;"},{"name":"bUniversity of California Davis Comprehensive Cancer Center, Sacramento;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Gregg","sequence":"additional","affiliation":[{"name":"cDepartment of Pathology and Laboratory Medicine and Genomic Shared Resource,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ma","sequence":"additional","affiliation":[{"name":"aDivision of Hematology\/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento;"},{"name":"bUniversity of California Davis Comprehensive Cancer Center, Sacramento;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yoneda","sequence":"additional","affiliation":[{"name":"dDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Moore","sequence":"additional","affiliation":[{"name":"eDepartment of Radiology, University of California Davis School of Medicine, Sacramento;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Daly","sequence":"additional","affiliation":[{"name":"fDepartment of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"gDepartment of Pathology, Kaiser Permanente Vallejo Medical Center, Vallejo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Williams","sequence":"additional","affiliation":[{"name":"hSutter Davis Medical Group, Davis, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhong","family":"Li","sequence":"additional","affiliation":[{"name":"aDivision of Hematology\/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento;"},{"name":"bUniversity of California Davis Comprehensive Cancer Center, Sacramento;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref161","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J Mol Diagn"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jtho.2015.12.105","article-title":"Transformation to SCLC after treatment with the ALK inhibitor alectinib","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jtho.2015.12.105","article-title":"Transformation to SCLC after treatment with the ALK inhibitor alectinib","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1200\/jco.2012.30.15_suppl.7526","article-title":"Continuation of ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant Mt non - small cell lung cancer abstract Abstract","volume":"30","author":"WeickhardtAJ","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4132\/jptm.2016.10.18","article-title":"Metastatic squamous cell carcinoma from lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor therapy","volume":"51","author":"Park","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2169\/internalmedicine.56.7452","article-title":"Histological transformation to large cell neuroendocrine carcinoma from lung adenocarcinoma harboring an EGFR mutation: an autopsy case report","volume":"56","author":"Moriya","year":"2017","journal-title":"Intern Med"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1759-7714.12217","article-title":"Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor","volume":"6","author":"Kim","year":"2015","journal-title":"Thorac Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9010","article-title":"Association of ALK resistance mutations by EML4-ALKvariant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC) [abstract]","volume":"35","author":"Ou","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","article-title":"A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics","volume":"14","author":"Ferrer","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","article-title":"A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics","volume":"14","author":"Ferrer","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JTO.0000000000000030","article-title":"Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays","volume":"9","author":"Li","year":"2014","journal-title":"J Thorac Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.10.012","article-title":"Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors","volume":"102","author":"Levacq","year":"2016","journal-title":"Lung Cancer"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2015-0497","article-title":"Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2015-0497","article-title":"Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/JTO.0b013e3182a407fa","article-title":"Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology","volume":"8","author":"Norkowski","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/JTO.0b013e3182a407fa","article-title":"Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology","volume":"8","author":"Norkowski","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/JTO.0000000000000571","article-title":"Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition","volume":"10","author":"Levin","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann Oncol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J Mol Diagn"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-13-3077","article-title":"U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive","volume":"20","author":"Malik","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/lungindia.lungindia_347_17","article-title":"Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: report of a case with review of literature","volume":"35","author":"Hui","year":"2018","journal-title":"Lung India"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","article-title":"Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-13-3077","article-title":"U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive","volume":"20","author":"Malik","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","article-title":"Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients","volume":"114","author":"Tian","year":"2017","journal-title":"Lung Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/JTO.0000000000000571","article-title":"Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition","volume":"10","author":"Levin","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","article-title":"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers","volume":"7","author":"Lin","year":"2009","journal-title":"Mol Cancer Res"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JTO.0000000000000030","article-title":"Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays","volume":"9","author":"Li","year":"2014","journal-title":"J Thorac Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","article-title":"Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients","volume":"114","author":"Tian","year":"2017","journal-title":"Lung Cancer"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","article-title":"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers","volume":"7","author":"Lin","year":"2009","journal-title":"Mol Cancer Res"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4132\/jptm.2016.10.18","article-title":"Metastatic squamous cell carcinoma from lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor therapy","volume":"51","author":"Park","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","article-title":"Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.10.012","article-title":"Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors","volume":"102","author":"Levacq","year":"2016","journal-title":"Lung Cancer"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/lungindia.lungindia_347_17","article-title":"Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: report of a case with review of literature","volume":"35","author":"Hui","year":"2018","journal-title":"Lung India"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1759-7714.12217","article-title":"Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor","volume":"6","author":"Kim","year":"2015","journal-title":"Thorac Cancer"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1200\/jco.2012.30.15_suppl.7526","article-title":"Continuation of ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant Mt non - small cell lung cancer abstract Abstract","volume":"30","author":"WeickhardtAJ","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2169\/internalmedicine.56.7452","article-title":"Histological transformation to large cell neuroendocrine carcinoma from lung adenocarcinoma harboring an EGFR mutation: an autopsy case report","volume":"56","author":"Moriya","year":"2017","journal-title":"Intern Med"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref421","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9010","article-title":"Association of ALK resistance mutations by EML4-ALKvariant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC) [abstract]","volume":"35","author":"Ou","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/4\/article-p297.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:13:39Z","timestamp":1663251219000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/4\/article-p297.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":66,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2019.7291","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}